Exploring the repurposing potential of telmisartan drug in breast cancer: an in-silico and in-vitro approach
- 24 February 2023
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anti-Cancer Drugs
- Vol. 34 (10), 1094-1103
- https://doi.org/10.1097/cad.0000000000001509
Abstract
Anticancer drug resistance is one of the biggest hurdles in the treatment of breast cancer. Drug repurposing is a viable option fordeveloping novel medical treatment strategies since this method is more cost-efficient and rapid. Antihypertensive medicines have recently been found to have pharmacological features that could be used to treat cancer, making them effective candidates for therapeutic repurposing. The goal of our research is to find a potent antihypertensive drug that can be repurposed as adjuvant therapy for breast cancer. In this study, virtual screening was performed using a set of Food and Drug Administration (FDA)-approved antihypertensive drugs as ligands with selected receptor proteins (EGFR, KRAS, P53, AGTR1, AGTR2, and ACE) assuming these proteins are regarded to have a significant role in hypertension as well as breast cancer. Further, our in-silico results were further confirmed by an in-vitro experiment (cytotoxicity assay). All the compounds (enalapril, atenolol, acebutolol, propranolol, amlodipine, verapamil, doxazosin, prazosin, hydralazine, irbesartan, telmisartan, candesartan, and aliskiren) showed remarkable affinity towards the target receptor proteins. However, maximum affinity was displayed by telmisartan. Cell-based cytotoxicity study of telmisartan in MCF7 (breast cancer cell line) confirmed the anticancer effect of telmisartan. IC50 of the drug was calculated to be 7.75 µM and at this concentration, remarkable morphological alterations were observed in the MCF7 cells confirming its cytotoxicity in breast cancer cells. Based on both in-silico and in-vitro studies, we can conclude that telmisartan appears to be a promising drug repurposing candidate for the therapeutic treatment of breast cancer.Keywords
This publication has 45 references indexed in Scilit:
- Small molecule induced reactivation of mutant p53 in cancer cellsNucleic Acids Research, 2013
- admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET PropertiesJournal of Chemical Information and Modeling, 2012
- Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activityProceedings of the National Academy of Sciences of the United States of America, 2012
- Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists—A perspectiveBioorganic & Medicinal Chemistry, 2010
- Ligand docking and binding site analysis with PyMOL and Autodock/VinaJournal of Computer-Aided Molecular Design, 2010
- The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancerOncology Reports, 2010
- VASCULAR ANGIOTENSIN AT2 RECEPTORS IN HYPERTENSION AND AGEINGClinical and Experimental Pharmacology and Physiology, 2008
- Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatmentInternational Journal of Urology, 2008
- Crystal structure of the human angiotensin-converting enzyme–lisinopril complexNature, 2003
- Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular DomainsCell, 2002